[BIND] BIND Therapeutics, Inc.

Overview

Type of security: Stock

Sector: Health Care

Industry: Major Pharmaceuticals

Market Capitalization:

Exchange: NASDAQ

The data is delayed by 15 minutes.

 

Price: 0.78 Change: 0 (0%)
Ext. hours: Change: 0 (0%)

chart BIND

Refresh chart

Description: BIND Therapeutics, Inc., a clinical-stage nanomedicine platform company, develops various targeted and programmable therapeutics. It is developing Accurins that are designed with specified physical and chemical characteristics to target specific cells or tissues and concentrate a therapeutic payload at the site of disease to enhance efficacy while minimizing adverse effects on healthy tissues. The company?s lead Accurin drug candidate includes BIND-014, a prostate-specific membrane antigen targeted Accurin that contains docetaxel and is in Phase 2 clinical trials for non-small cell lung cancer and metastatic castrate-resistant prostate cancer. It has collaboration agreements to develop Accurins based on therapeutic payloads from their product pipelines with Amgen, Inc.; Pfizer Inc.; and AstraZeneca AB. The company was formerly known as BIND Biosciences, Inc. and changed its name to BIND Therapeutics, Inc. in April 2013. BIND Therapeutics, Inc. was founded in 2006 and is headquartered in Cambridge, Massachuset

Fundamental Ratios
Shares Outstanding EPS-1.98 EPS Growth - 4 Quarters EPS Growth - Q/Q
EPS Growth - Y/Y Sales Growth - 4 Quarters 78.28% Sales Growth - Q/Q44.35% P/E-0.39
P/E To EPS Growth P/S P/BV Price/Cash Per Share
Price/Free Cash Flow ROA-42.5% ROE-77.87% ROI
Current Ratio5.49 Quick Ratio Long Term Debt/Equity0.24 Debt Ratio0.3
Gross Margin Operating Margin-253.29% Net Profit Margin-245.59% Dividend Payout Ratio
Dividend Yield
Fundamental Data
Cash From Financing Activities31.72 M Cash From Investing Activities-14.31 M Cash From Operating Activities-9.01 M Gross Profit
Net Profit-8.31 M Operating Profit-8.56 M Total Assets76.54 M Total Current Assets68.25 M
Total Current Liabilities12.44 M Total Debt14.5 M Total Liabilities34.77 M Total Revenue4.38 M
Technical Data
High 52 week5.47 Low 52 week0.35 Last close0.78 Last change-10.34%
RSI65.43 Average true range0.13 Beta0.65 Volume
Simple moving average 20 days28.61% Simple moving average 50 days57.58% Simple moving average 200 days-60.42%
Performance Data
Performance Week52.94% Performance Month100% Performance Quart-46.21% Performance Half-55.68%
Performance Year-84.43% Performance Year-to-date-65.94% Volatility daily17.21% Volatility weekly38.48%
Volatility monthly78.86% Volatility yearly273.17% Relative Volume0% Average Volume1.19 M
New High New Low

News

2016-08-16 06:20:40 | Bind Therapeutics reports 2Q loss

2016-07-26 17:48:09 | BIND Therapeutics Determines Pfizer's $40 Million Bid Is Highest and Best in 363 Auction for Substantially All of BIND's Assets

2016-07-26 17:27:00 | BIND Therapeutics Determines Pfizer’s $40 Million Bid Is Highest and Best in 363 Auction for Substantially All of BIND’s Assets

2016-07-25 07:58:08 | BIND Therapeutics Announces Two Bidders Join Pfizer's Stalking Horse Bid in Auction for BIND's Assets

2016-07-25 07:00:00 | BIND Therapeutics Announces Two Bidders Join Pfizer’s Stalking Horse Bid in Auction for BIND’s Assets

2016-07-01 17:51:01 | BIND Therapeutics Files Motion for Sale of Assets After Accepting Stalking Horse Bid from Pfizer Inc.

2016-07-01 17:30:00 | BIND Therapeutics Files Motion for Sale of Assets After Accepting Stalking Horse Bid from Pfizer Inc.

2016-06-17 10:19:45 | BIND Therapeutics Announces Resignation of Directors Affiliated with Polaris Partners

2016-06-17 09:00:00 | BIND Therapeutics Announces Resignation of Directors Affiliated with Polaris Partners

2016-05-19 19:02:37 | ETF’s with exposure to BIND Therapeutics, Inc. : May 19, 2016

2016-05-19 08:32:03 | BIND Therapeutics Provides Update on Chapter 11 Proceedings and Announces Agreement with Hercules Technology III, L.P.

2016-05-19 08:00:00 | BIND Therapeutics Provides Update on Chapter 11 Proceedings and Announces Agreement with Hercules Technology III, L.P.

2016-05-18 13:04:21 | BIND THERAPEUTICS, INC Financials

2016-05-17 12:20:14 | BIND Therapeutics, Inc. :BIND-US: Earnings Analysis: Q1, 2016 By the Numbers

2016-05-10 08:18:05 | Data Published in Journal of Controlled Release Demonstrate Flexibility of ACCURINS® to Encapsulate a Broad Range of Physically and Chemically Diverse Payloads with High Encapsulation Efficiency and Tunable Release Kinetics

2016-05-10 08:00:00 | Data Published in Journal of Controlled Release Demonstrate Flexibility of ACCURINS® to Encapsulate a Broad Range of Physically and Chemically Diverse Payloads with High Encapsulation Efficiency and Tunable Release Kinetics

2016-05-09 07:23:30 | Bind Therapeutics reports 1Q loss

2016-05-09 07:16:03 | BIND Therapeutics Reports First Quarter 2016 Financial Results and Provides Business Update

2016-05-09 07:00:00 | BIND Therapeutics Reports First Quarter 2016 Financial Results and Provides Business Update

2016-05-05 16:44:15 | Hercules Announces First Quarter 2016 Financial Results and Quart ...

2016-05-05 08:36:12 | Is a Surprise Coming for BIND Therapeutics BIND This Earnings Season?

2016-05-05 08:11:14 | BIND Therapeutics Announces Collaboration with Affilogic to Provide BIND with Access to Targeting Ligands that are Key Modulators of Anti-tumor Immunity

2016-05-05 08:00:00 | BIND Therapeutics Announces Collaboration with Affilogic to Provide BIND with Access to Targeting Ligands that are Key Modulators of Anti-tumor Immunity

2016-05-03 16:10:03 | BIND Therapeutics to Report First Quarter 2016 Financial Results on May 9, 2016

2016-05-03 16:01:00 | BIND Therapeutics to Report First Quarter 2016 Financial Results on May 9, 2016

2016-05-02 13:44:12 | 3 Companies Filed For Chapter 11 Bankruptcy Today

2016-05-02 06:40:01 | BIND Therapeutics Files For Bankruptcy Protection Under Chapter 11

2016-05-02 06:20:08 | BIND Therapeutics Initiates Voluntary Chapter 11 Bankruptcy Protection Proceeding

2016-05-02 06:00:00 | BIND Therapeutics Initiates Voluntary Chapter 11 Bankruptcy Protection Proceeding

2016-04-06 10:33:00 | PeptiDream Announces Research Collaboration with BIND Therapeutics

2016-04-06 09:50:07 | BIND Therapeutics Reports Phase 2 Data from iNSITE 1 and iNSITE 2 Trials with BIND-014 and Provides Strategic Update

2016-04-06 09:25:00 | BIND Therapeutics Reports Phase 2 Data from iNSITE 1 and iNSITE 2 Trials with BIND-014 and Provides Strategic Update

2016-03-28 08:01:00 | Biotech Sector Report Analyst; Expecting FDA Results

2016-03-15 07:13:58 | Bind Therapeutics reports 4Q loss

2016-03-15 07:00:00 | BIND Therapeutics Reports Fourth Quarter and Full Year 2015 Financial Results and Announces Shift in Research and Discovery Strategy to Focus on Developing Innovative Medicines Based on ACCURINS® Platform

2016-01-27 08:26:34 | BIND Therapeutics Provides Enrollment Update for Phase 2 iNSITE 1 and iNSITE 2 Trials with BIND-014

2016-01-07 08:12:27 | BIND Therapeutics Presents Complete Data on Clinical Activity of BIND-014 in Patients with Metastatic Castration-Resistant Prostate Cancer mCRPC at the 2016 Genitourinary Cancers Symposium

2016-01-05 07:38:12 | BIND Therapeutics to Present at Biotech Showcase 2016

2015-12-16 07:35:07 | BIND Therapeutics Appoints Jonathan Yingling, Ph.D., as Chief Scientific Officer

2015-12-14 07:42:28 | BIND Therapeutics to Advance BIND-014 Squamous Histology Non-Small Cell Lung Cancer Cohort to Second Stage of iNSITE 1 Trial

2015-11-25 14:49:20 | Do Hedge Funds Love Mast Therapeutics Inc MSTX?

2015-11-18 08:25:04 | BIND Therapeutics Announces Initiation of Clinical Studies with Accurin AZD2811 in Solid Tumors

2015-11-02 07:34:35 | Bind Therapeutics reports 3Q loss

2015-08-06 07:06:56 | Bind Therapeutics reports 2Q loss

2015-05-07 08:52:10 | Bind Therapeutics reports 1Q loss

2015-04-11 09:15:04 | 7 Analyst Stocks Under $10 With Massive Upside Calls

2015-03-11 07:18:27 | Bind Therapeutics reports 4Q loss

2015-02-10 12:41:00 | Funds Reveal New Positions in Peabody Energy Corporation BTU, BIND Therapeutics Inc BIND

2014-11-06 11:22:00 | Bind Therapeutics posts 3Q loss